Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing real-world safety and effectiveness study of Zerbaxa for hospital-acquired and ventilator-associated bacterial pneumonia in adults in China
CTR20263977Phase 4Active
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftolozane + tazobactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Merck & Co.. Started Oct 2026; status: active.
02
Drugs
ceftolozane + tazobactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20263977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263977.